On September 6, 2022 Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, reported members of its management team will participate at the following investor conferences in September 2022 (Press release, Alpine Immune Sciences, SEP 6, 2022, View Source [SID1234619046]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright 24th Annual Global Investment Conference
Date: Monday, September 12, 2022
Time: 7:00 a.m. PT/10:00 a.m. ET
Event: Corporate Presentation & One-on-One Investor Meetings
Presenter: Remy Durand, PhD, Chief Business Officer, Alpine Immune Sciences, Inc.

Morgan Stanley 20th Annual Global Healthcare Conference
Date: Wednesday, September 14, 2022
Event: One-on-One Investor Meetings

A link to the H.C. Wainwright corporate presentation will be available online in the investor relations section of the Company’s website at View Source and will be available on the Company website for 90 days following the webcast. Investors interested in participating in One-on-One meetings at these conferences should reach out to their sales representatives at H.C. Wainwright and Morgan Stanley for more information.

On September 6, 2022 Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives, reported that a pre-recorded corporate presentation by Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer, will become available for on-demand viewing at the H.C. Wainwright 24th Annual Global Investment Conference, on Monday, September 12, 2022, at 7:00 a.m. ET (Press release, Aileron Therapeutics, SEP 6, 2022, View Source [SID1234619064]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be available under the Investors & Media section of the company’s website at aileronrx.com. A replay of the webcast will be archived on the Aileron website for approximately 30 days following the presentation.

On September 6, 2022 (GLOBE NEWSWIRE) — Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, reported that Mina Sooch, MBA, Founder and CEO will present a corporate overview at the H.C. Wainwright 24th Annual Global Investment Conference being held September 12-14, 2022 (Press release, Ocuphire Pharma, SEP 6, 2022, View Source [SID1234619082]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright 24th Annual Global Investment Conference – September 12-14, 2022

If you are interested in arranging a 1×1 meeting request, please contact your bank/conference representative or [email protected]. For more details, please see the Investors and Events section of Ocuphire’s corporate website.

On September 6, 2022 Elephas Biosciences Corporation (Elephas), a private company, reported that it has raised $41.5 million in Series B funding (Press release, Elephas Biosciences, SEP 6, 2022, View Source [SID1234619100]). ARCH Venture Partners led the round, and were joined by new investors, Moore Strategic Ventures and Tao Capital Partners . Continuing investments were made by Northpond Ventures, Sands Capital, and WARF Ventures. Prior investments include $20 million from the Series A and $8 million from the founder and early seed investors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Elephas is developing an oncology diagnostics platform to predict response to immunotherapy. The platform utilizes live fragments from a patient biopsy and treats those fragments with potential therapies and combinations. The latest advances in cancer biology combined with multi-modal imaging are used to assess how patients will respond before beginning treatment.

Elephas is launching two human clinical trials on the platform in the next quarter and plans to share initial clinical data in 2023. The company also plans to make the platform available to biopharma researchers next year. Oncology drugs remain the largest pharmaceutical therapeutic area, with immunotherapies emerging in the last decade as effective and powerful tools in the fight against cancer.

"Our mission at Elephas is to improve care for cancer patients," stated Maneesh Arora, founder and CEO of Elephas. "We are grateful for the support of these world-class venture firms who believe in what we are doing and are committed to helping us get there."

"Technology that will allow patients to receive the most effective therapy quickly, before time and resources are spent on ineffective options, will change the game for those diagnosed with cancer," ARCH Venture Partners’ Paul Berns added. "We are excited to partner with the company to bring this novel solution to patients."

XMS Capital Partners acted as financial advisor to the company.

ARCH Venture Partners’ Paul Berns will join the Elephas board of directors and ARCH’s Keith Crandell will be joining as a board observer. This follows the recent appointment by the company of Steven Galson, the former director of the Center for Drug Evaluation and Research at FDA, as independent director.

On September 6, 2022 Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, reported that Susan Molineaux, Ph.D., the company’s founder, president and chief executive officer, will present at the H.C. Wainwright 24th Annual Global Investment Conference, being held September 12-14 both virtually and in New York, NY (Press release, Calithera Biosciences, SEP 6, 2022, View Source [SID1234619118]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be available for on-demand viewing starting Monday, September 12, 2022, at 7:00 a.m. Eastern Time, and can be accessed through the Investors section of the Company’s website at www.calithera.com. The replay of the webcast will be available on the Company’s website for 30 days.